News | June 30, 2024
Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals
Laurus Labs receives EIR from USFDA for API facilities
Laurus Labs receives EIR from USFDA for API facilities
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Subscribe To Our Newsletter & Stay Updated
